A composition and method for polyherbal capsule formulation and preclinical evaluation for diabetes mellitus management

IN607037BActive Publication Date: 2026-10-26VAISHALI KESHAVRAO CHAVAN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202621022171
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2026-02-25
Publication Date
2026-10-26
Estimated Expiration
2046-02-25

AI Technical Summary

Technical Problem

Conventional diabetes management strategies, whether synthetic or herbal, face issues such as side effects, variability in extract quality, lack of standardization, and inconsistent dosing, failing to adequately address the multifactorial aspects of diabetes, including inflammation and oxidative stress.

Method used

A synergistic polyherbal capsule formulation using standardized extracts of Quassia amara, Swertia chirata, and Trigonella foenum-graecum, combined with rigorous quality control measures, to modulate pancreatic functionality, reduce blood glucose levels, and attenuate pro-inflammatory cytokines, ensuring consistent and effective diabetes management.

Benefits of technology

The formulation effectively reduces blood glucose levels, enhances insulin secretion, mitigates oxidative stress, and restores pancreatic and hepatic histopathology, providing a safe, reliable, and culturally acceptable therapeutic option with minimal side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a polyherbal capsule formulation and its preparation for diabetes mellitus management. It comprises a standardized herbal extract blend formulated from extracts of Quassia Amara, Swertia chirata, and Trigonella foenum-graecum obtained via ethanol extraction and drying to maintain moisture below 5%, followed by milling and sieving through a 60‐mesh to ensure uniform particle size. The capsule undergoes rigorous pre- and post-formulation quality control tests such as weight variation, disintegration, and dissolution. Additionally, the invention encompasses a method for preclinical evaluation using a streptozotocin-induced diabetic rat model and correlating findings to potential human dosing.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD:

[0001] The invention broadly relates to a composition and method for polyherbal capsule formulation and preclinical evaluation for diabetes mellitus management.BACKGROUND:

[0002] The prevalence of diabetes mellitus has increased globally, with patients experiencing complications such as poor glycemic control, elevated inflammatory markers, and pancreatic stress. Conventional management approaches have primarily focused on reducing blood glucose levels, often leaving unresolved issues related to inflammation and oxidative stress. The technical field of this invention relates to pharmaceutical formulations and the development of natural therapies for metabolic disorders.

[0003] Existing solutions in diabetes management include synthetic antidiabetic agents and herbal formulations. Synthetic drugs typically target glucose reduction and may involve complex chemical synthesis and formulation strategies. Herbal formulations have been explored as alternatives for years, drawing on traditional knowledge and empirical evidence to manage hyperglycemia and associated metabolic disturbances.

[0004] Several attempts were made for providing herbal tratment for management of diabetes in prior art:

[0005] IN202311048124 discloses a synergistic natural herbal Composition and its formulation thereof, designed to manage diabetes and improve overall health. The composition comprises a precise combination of herbs and plants known for their potential blood sugar- lowering effects and other health benefits. The key ingredients include Eugenia jambolana, Momordica charantia, Gymnema sylvestre, Trigonella foenum-graecum, Cinnamomum tamala, and Withania coagulans, among others. The composition is prepared using high- quality herbs, subjected to a thorough cleaning and drying process, followed by grinding and precise mixing. The inventive herbal composition works by regulating blood sugar levels, improving insulin sensitivity, promoting pancreatic cell regeneration, and providing antioxidant and anti-inflammatory effects. The invention provides a natural, cost-effective, and potentially safer alternative for individuals seeking alternative or complementary treatment options for diabetes.

[0006] IN202341034925 discloses a herbal formulation for the prevention and treatment of diabetes mellitus. The formulation comprises a synergistic blend of specific herbal ingredients, including Momordica charantia (bitter melon), Gymnema sylvestre, Trigonella foenum-graecum (fenugreek), Curcuma longa (turmeric), Azadirachta indica (neem), Syzygium cumini (black plum), Terminalia arjuna, Emblica officinalis (Indian gooseberry), and Withania somnifera (ashwagandha). The formulation is prepared by obtaining dried plant materials or extracts of the aforementioned herbs, which undergo meticulous quality control measures. The ingredients are weighed in predetermined proportions and processed to obtain a fine powder or extract.

[0007] WO2009098702 discloses a hypoglycemic herbal extract composition for reducing blood sugar levels in mammals especially humans suffering from diabetes mellitus comprising, dried aqueous extract of green young fruits of Momordica Charantia; and dried aqueous extract other biological additives like herbs / medicinal plants Enicostemma Littorale, Eugenia Jambolana, Swertia Chirata, Trigonella Foenum, Azadirachta Indica, Gymnema Sylvestre, Emblica Officinalis, Tinospora Cordifolia, Picrorhiza Kurroa, and Curcuma Longa, dried extracts of Momordica Charantia and other biological extracts are dried and mixed to obtain final composition.

[0008] US6042834 discloses an herbal composition for the treatment of diabetes, comprising 15 percent by weight of dried, powdered seeds of Trigonella foenum-graecum; 23 percent by weight of dried, powdered seeds of Nigella sativa; 10 percent by weight of dried, powdered leaves of Origanum vulgare; 10 percent by weight of dried, powdered sap of Rosmarinus officinalis; 15 percent by weight of dried, powdered beans of Lupinus termis; 12 percent by weight of dried, powdered black leaves of Lawsonia inermis; and 15 percent by weight of dried, powdered seeds of Foeniculum vulgare. The herbal composition may be administered in non-encapsulated powder form or in capsule form. A method of treatment for diabetes using the herbal composition comprises monitoring a diabetic patient's blood sugar level; administering to the patient the herbal composition in an amount of about 9 g per day for at least about 60 days until such date as the patient's blood sugar level achieves and maintains normalcy; administering to the patient the herbal composition in the amount of about 6 g per day for about another 7 days; administering to a patient the herbal composition in the amount of about 3 g per day for about another 14 days; and discontinuing administration, or, alternatively, continuing administration of the herbal composition as necessary for the patient at about less than or equal to 3 g per day of the herbal composition.

[0009] However, several limitations are apparent in these prior art strategies. Synthetic drugs often result in side effects such as gastrointestinal discomfort and hypoglycemia, and their monotherapeutic approach may not sufficiently address the multifactorial aspects of the disease. Likewise, existing herbal preparations are frequently compromised by variability in extract quality, lack of standardization, and technical challenges in ensuring dosage uniformity.

[0010] In view of these deficiencies, there arises a need for an improved approach, as exemplified by the present invention to provide a more reliable and integrated solution for diabetes treatment without compromising on safety or efficacy.OBJECT OF THE INVENTION:

[0011] One object of the invention is to provide a synergistic polyherbal formulation comprising standardized extracts of Quassia amara, Swertia chirata, and Trigonella foenum-graecum that effectively reduces blood glucose levels through the modulation of pancreatic functionality and attenuation of pro-inflammatory cytokines, thereby delivering a comprehensive antidiabetic therapeutic effect.

[0012] Another object of the invention is to provide a method for assessing antidiabetic efficacy via rigorous in vitro evaluation of key digestive enzymes such as α amylase and α glucosidase, as well as detailed in vivo studies using a streptozotocin-induced diabetic rat model, which collectively yield quantitative measures of hypoglycemic action and dose-dependent therapeutic responses.

[0013] Yet another object of the invention is to furnish a standardized herbal capsule formulation that incorporates meticulously optimized quality control parameters-such as moisture content, particle size, bulk and tapped densities, weight variation, and disintegration profiles-to ensure homogeneous drug delivery and consistent pharmacodynamic performance.

[0014] A further object of the invention is to accurately calculate the human equivalent dose (HED) for practical clinical application by employing established body surface area conversion factors from preclinical animal data, thus facilitating a safe and efficacious transition from laboratory studies to human use.

[0015] Another object of the invention is to improve overall metabolic balance in diabetic conditions by enhancing lipid profiles and boosting endogenous antioxidant enzyme activities (including SOD, CAT, and GSH), thereby contributing to the mitigation of oxidative stress and restoration of tissue health.

[0016] Yet another object of the invention is to protect and restore pancreatic and hepatic histopathological architecture compromised by streptozotocin-induced damage, ensuring long-term structural and functional integrity of the affected tissues.

[0017] An object of the invention is to elucidate the molecular mechanism underlying the antidiabetic activity by integrating advanced molecular docking studies, using tools such as AutoDock Tools, PyMOL, and Discovery Studio Visualizer, to reveal the binding interactions of bioactive phytochemicals with target proteins involved in glucose regulation.

[0018] Another object of the invention is to incorporate early-stage ADMET profiling of the identified bioactive compounds via in silico methods, thereby predicting their absorption, distribution, metabolism, excretion, and toxicity profiles to support their safety and efficacy in further drug development.

[0019] Finally, an object of the invention is to leverage indigenous medicinal plant resources to develop an affordable and culturally acceptable antidiabetic treatment that overcomes the drawbacks of conventional single-agent therapies by offering a multi-targeted, synergistic approach with enhanced therapeutic benefits and minimized side effects.SUMMARY OF THE INVENTION:

[0020] The present invention is described in the following sections by various embodiments. However, it should be understood that the invention can be implemented in various forms and is not limited to the specific embodiment provided herein.In the context of the present disclosure, it should be understood that the described embodiments in this section are put forth for illustrative purposes only. Those skilled in the art will appreciate that various modifications, adaptations, and alternative designs may be employed without departing from the scope and spirit of the invention. Accordingly, the present invention should not be limited to the specific embodiments illustrated herein, but rather should be construed according to the claims and description that follow.

[0021] In one aspect the present invention provides a polyherbal capsule formulation for diabetes mellitus management. The formulation comprises a standardized herbal extract blend prepared from an extract of Quassia amara, an extract of Swertia chirata and an extract of Trigonella foenum-graecum, each obtained by subjecting the corresponding raw plant material to a standardized extraction process. In this process, the extracts are dried to achieve a moisture content below 5%, milled and passed through a 60‐mesh sieve to yield a powder of uniform particle size. The invention further comprises one or more pharmaceutically acceptable excipients that improve the powder flow properties and facilitate uniform blending with the herbal extract blend by geometric dilution. The blended powder is then encapsulated within a hard gelatin capsule to provide a predetermined dose. The capsule formulation is subjected to rigorous pre-formulation quality control tests, including moisture content determination, particle size analysis and density measurements, and to comprehensive post-formulation tests such as weight variation, disintegration and dissolution testing under pharmacopeial conditions. This integration of standardized extraction, precise milling, and systematic encapsulation ensures high uniformity and consistency in delivering the active compounds for effective diabetes management.

[0022] An important advantage offered by the formulation of present invention is its rigorous standardization and quality control approach, which results in enhanced reproducibility and reliable therapeutic performance. The precise control of the extraction and blending process ensures consistent bioavailability of the active phytochemicals, thereby contributing to effective modulation of blood glucose levels, improved insulin secretion, and attenuation of proinflammatory cytokines. This unique combination of scientifically validated extraction methods and comprehensive quality evaluations directly addresses the shortcomings of conventional single-agent antidiabetic therapies, which can suffer from inconsistent dosing and limited efficacy.

[0023] In another aspect, the present invention provides the standardized extraction process comprises ethanol extraction followed by drying to achieve a moisture content below 5%.

[0024] In yet another aspect, the present invention provides a method for preparing a polyherbal capsule formulation for diabetes mellitus management.

[0025] In accordance with an embodiment of the present invention, a method for preclinical evaluation of the polyherbal capsule formulation for diabetes mellitus management is provided. The evaluation method comprises orally administering the capsule formulation to a streptozotocin-induced diabetic rat model, monitoring critical biochemical parameters such as blood glucose levels, plasma insulin levels, lipid profiles and antioxidant enzyme activities, and evaluating the inhibitory effects of the herbal extract blend on α-amylase and α glucosidase using spectrophotometric assays to calculate IC50 values. Furthermore, in vitro enzymatic inhibition studies complement the in vivo assessments, establishing a scientific rationale for the formulation's antidiabetic activity.BRIEF DESCRIPTION:

[0026] The present invention is subsequently described herein using various embodiments. Throughout this description, the term 'may' is used in a permissive sense, indicating the potential to, rather than in a mandatory sense, indicating a requirement. Additionally, the words 'a' or 'an' signify at least one, and the word 'plurality' signifies 'one or more' unless otherwise specified. Moreover, the terminology and phraseology employed herein are solely for descriptive purposes and should not be construed as limiting in scope. Terms such as 'including', 'comprising', 'having', 'containing', or 'involving', and their variations, are intended to be broad and encompass the listed subject matter thereafter, as well as equivalents and additional subject matter not explicitly mentioned, and should not be interpreted as excluding other additives, components, integers, or steps. Similarly, the term 'comprising' is considered synonymous with the terms 'including' or 'containing' for applicable legal purposes.

[0027] In one embodiment, the present invention discloses a polyherbal capsule formulation for the management of diabetes mellitus that integrates comprehensive pharmacological evaluation and the formulation of standardized herbal extracts into a single dosage form.

[0028] In another embodiment, the present invention utilizes specific extracts derived from indigenous medicinal plants, namely Quassia amara, Swertia chirata, and Trigonella foenum-graecum, to provide a synergistic antidiabetic effect. The formulation is designed to modulate blood glucose levels, enhance insulin secretion, inhibit carbohydrate digestive enzymes, and mitigate inflammatory cytokines, thereby addressing several metabolic dysfunctions associated with diabetes. The invention also incorporates extensive quality control measures and preclinical evaluations to ensure consistency, efficacy, and reproducibility of the therapeutic effects.

[0029] In another embodiment, the present invention the combination of multiple standardized herbal extracts prepared by controlled ethanol extraction, drying, and milling to obtain a uniform powder with a moisture content below 5%. The extracts, referred to herein as standardized herbal extract blend, are combined with pharmaceutically acceptable excipients to optimize the flow properties of the blend for capsule filling into hard gelatin capsules. The formulation is further substantiated by rigorous in vitro and in vivo evaluations, including enzyme inhibition assays and animal studies using a streptozotocin-induced diabetic rat model, as well as advanced molecular docking and ADMET analyses to confirm binding interactions and predict pharmacokinetic properties.

[0030] In yet another embodiment, the active herbal extracts component comprises standardized extracts of Quassia amara, Swertia chirata and Trigonella foenum-graecum. Each extract is prepared by subjecting the respective raw plant materials to an ethanol extraction process followed by drying until the moisture content is reduced below 5%. The dried extracts are milled and passed through a 60‐mesh sieve to obtain a substantially uniform powder. The extracts, when combined, yield a herbal extract blend that functions by modulating blood glucose levels, enhancing plasma insulin concentrations, and downregulating cytokines such as TNF α and IL 6. The bioactive phytochemicals present in these extracts are responsible for the marked effects on pancreatic function and antioxidant enzyme activity.

[0031] The capsule formulation and powder blend component involves blending the active herbal extract powders with one or more pharmaceutically acceptable excipients in a manner that ensures a homogeneous distribution. The blending is carried out by geometric dilution to achieve a uniform powder composition that facilitates controlled dosing when filled into hard gelatin capsules. In one embodiment, the powder is processed through a manual capsule filling machine wherein each capsule is designed to contain a predetermined dose, for example, 450 mg per capsule, with an additional allowance of 2-5% extra powder to compensate for process losses. The geometry of the blend, including particle size distribution and flow properties, is carefully controlled to ensure uniform weight variation and reliable disintegration and dissolution profiles.

[0032] In yet another embodiment, the present invention provides a method for preparing a polyherbal capsule formulation for diabetes mellitus management. The method comprises preparing standardized extracts of Quassia amara, Swertia chirata and Trigonella foenum-graecum by subjecting the raw plant materials to ethanol extraction and subsequent drying to achieve a moisture content below 5%, milling the dried extracts and passing them through a 60‐mesh sieve to obtain uniform particle sizes, and finally blending the extracts by geometric dilution with one or more pharmaceutically acceptable excipients to form a homogenous herbal extract blend. The blend is then encapsulated into hard gelatin capsules to provide a predetermined dose per capsule. Additionally, the encapsulated formulation is subjected to thorough pre-formulation and post-formulation quality control tests including moisture content determination, particle size analysis, weight variation, disintegration and dissolution testing.

[0033] The pre- and post-formulation quality control components are integral to the invention, providing structural and functional verification of the product. Prior to encapsulation, the blended powder is subjected to critical tests such as moisture content determination, particle size analysis, bulk and tapped density measurements, and angle of repose evaluations. The results of these tests guide adjustments to the blending process. After encapsulation, the filled hard gelatin capsules are evaluated through weight variation tests, disintegration tests (using a USP disintegration apparatus maintained at 37°C in 0.1 N HCl), and dissolution tests (typically targeting at least 80% of the active compounds released within 60 minutes). These quality control measures ensure consistency and predictability in the release profile of the bioactive components.

[0034] The invention further includes an in vitro enzymatic inhibition evaluation component wherein the herbal extract blend is assessed for its ability to inhibit digestive enzymes such as α amylase and α glucosidase. In one embodiment, reaction mixtures are prepared using designated substrates, for example, starch azure in a Tris-HCl buffer with CaCl₂ for α amylase, and p-nitrophenyl-α-D-glucopyranoside in a phosphate buffer for α glucosidase. The formulation is introduced at varying concentrations and the reactions are incubated under controlled temperature and pH conditions. Following the completion of the enzymatic reactions, inhibitory effects are quantitatively measured spectrophotometrically by calculating the IC50 values, thereby supporting the mechanistic basis of postprandial blood glucose control.

[0035] An in vivo antidiabetic evaluation module is provided to substantiate the efficacy of the herbal formulation in a biological system. In one embodiment, diabetes is induced in Wistar rats by the administration of streptozotocin (STZ) at a dose of approximately 50 mg / kg, dissolved in a freshly prepared sodium citrate buffer, to selectively impair pancreatic β-cell function. Following the confirmation of diabetic status through blood glucose measurements, the herbal capsule formulation is administered orally, and animals are monitored periodically for biochemical parameters including blood glucose, plasma insulin, lipid profiles, and antioxidant enzyme levels (SOD, CAT, GSH). Histopathological examinations of the pancreas and liver further validate the protective and restorative effects of the formulation against diabetic tissue damage.

[0036] In another aspect, the present invention provides the pharmaceutically acceptable excipients include at least one flow-enhancing agent selected from the group comprising microcrystalline cellulose, starch and lactose. The use of such excipients further facilitates uniform blending by geometric dilution with the active herbal extract blend, thus ensuring that the composition exhibits consistent flow properties during the encapsulation process and maintains dose uniformity.

[0037] In accordance with an embodiment of the present invention, a method for correlating preclinical efficacy to potential human application of the polyherbal capsule formulation is provided. This method comprises calculating a human equivalent dose (HED) from the animal study data obtained from the streptozotocin-induced diabetic rat model using standardized body surface area conversion techniques, and comparing the calculated HED with the formulated capsule dosage. This approach facilitates the establishment of an appropriate dosing regimen for potential clinical evaluations.

[0038] In accordance with an embodiment of the present invention, advanced in silico analyses such as molecular docking and ADMET profiling are conducted to substantiate the antidiabetic mechanism at the molecular level. In these studies, key phytochemicals present in the extracts-such as isoquassin, neoquassin, amarogentin, swertiamarin, quercetin and trigonelline-are modeled and docked against target proteins, including receptors involved in GLP-1 signaling. Complementary binding energy calculations and ADMET predictions provide supportive evidence for both the binding affinity and safety profile of the herbal constituents. These computational insights interface with the in vitro and in vivo data to reinforce the novel therapeutic approach embodied within the formulation.

[0039] Dissolution and content uniformity testing components play a key role in ensuring that the formulated capsules deliver a consistent therapeutic dose. In one embodiment, dissolution testing is performed using a paddle apparatus with a dissolution medium maintained at 37°C and pH adjusted to approximately 1.2, where aliquots are sampled at defined intervals to confirm that the dissolution profile meets the targeted release criteria. Concurrently, content uniformity is verified by analyzing samples from multiple capsules using spectrophotometric methods after appropriate extraction and filtration, thereby ensuring that each unit conforms to the defined dosage requirements.

[0040] A further embodiment employs molecular docking and ADMET analysis to provide computational evidence supporting the efficacy and safety of the formulation. In this embodiment, virtual models of bioactive phytochemicals such as isoquassin, neoquassin, amarogentin, swertiamarin, quercetin, and trigonelline are prepared and docked onto target proteins associated with glucose regulation, such as the GLP 1 receptor. Software tools are used to simulate the binding interactions, calculate binding energies, and visualize the molecular interactions, thereby providing insight into the potential mechanism of action of the formulation. In silico ADMET profiling is conducted on these compounds to predict their pharmacokinetic behavior and toxicity profiles, ensuring that the selected constituents exhibit favorable absorption, distribution, metabolism, and excretion characteristics and minimal adverse effects.

[0041] The invention is implemented through a series of coordinated steps that begin with the preparation of the raw plant materials. In one embodiment, raw materials from Quassia amara, Swertia chirata, and Trigonella foenum-graecum are collected, dried, and milled following standardized extraction procedures. The resulting powders are combined by geometric dilution with the aid of pharmaceutically acceptable excipients to form a homogeneous blend. The blend is thereafter encapsulated in hard gelatin capsules using a controlled manual filling process, during which environmental conditions such as temperature and humidity are tightly regulated to prevent moisture uptake. Subsequent quality control tests ensure that the powder blend exhibits acceptable physical properties, and that the final capsules comply with pharmacopeial standards in respect of weight variation, disintegration, and dissolution.

[0042] The evaluation of antidiabetic efficacy is carried out using both in vitro and in vivo methods. In one embodiment, in vitro assays employing enzymatic inhibition of α amylase and α glucosidase provide quantitative measures of the capsule's potential to reduce carbohydrate breakdown, while in vivo studies using a streptozotocin-induced diabetic rat model demonstrate the formulation's ability to reduce blood glucose levels, enhance insulin secretion, and improve the lipid profile. The animal studies also encompass histopathological analyses that verify the restoration of pancreatic and hepatic architecture. The data obtained from these studies further serve as the basis for calculating a human equivalent dose (HED) using body surface area conversion techniques, thereby bridging the preclinical evaluations with potential clinical applications.

[0043] Various embodiments of the present invention may include modifications such as the substitution or addition of alternative pharmaceutically acceptable excipients to further improve the flow properties or stability of the powder blend. An embodiment of the present invention contemplates the use of different extraction methods, such as supercritical fluid extraction, provided that the bioactive compounds are not adversely affected. Additional embodiments may incorporate variations in the capsule size or the ratio of extracts to accommodate different dosing requirements, while the in vitro and in vivo evaluation protocols may be adjusted in accordance with evolving pharmacopeial guidelines.

[0044] The invention offers significant benefits in managing diabetes mellitus by combining multiple complementary mechanisms to achieve glycemic control. The standardized herbal extract blend, processed under tightly controlled conditions, ensures reproducible dosing and favorable pharmacokinetic properties. The integrated evaluation using both biochemical assays and computational modeling provides a robust scientific foundation, while the extensive quality control measures guarantee a safe, consistent, and effective product. These technical features collectively enable the formulation to overcome limitations associated with traditional monotherapy, offering an efficacious and culturally acceptable therapeutic alternative.

[0045] Various modifications to these embodiments are evident to those skilled in the art based on the description. The principles associated with the various embodiments described herein can be applied to additional embodiments. Consequently, the description is not intended to be limited to the embodiments but aims to provide the broadest scope consistent with the principles and the innovative and inventive features disclosed or suggested herein. Therefore, the invention is expected to encompass all other such alternatives, modifications, and variations falling within the scope of the present invention.Example No. 01: Formulation of Herbal Capsules:Ingredient Quantity per Capsule (mg)Swertia chirata extract 150Trigonella foenum-graecum extract 150Quassia amara extract 150Total per capsule 450 mgProcedure:1. Accurately weigh all ingredients as per the formula.2. Pass all extracts and excipients through a #60 mesh sieve to ensure uniform particle size.3. Mix Swertia chirata, Fenugreek, and Bitter wood extracts using geometric dilution method.4. Fill 450 mg of the final blend into size '0' hard gelatin capsules using a manual capsule filling machine.5. Store capsules in airtight amber containers with desiccant to prevent moisture absorption.Evaluation of Herbal capsule formulations: 1.Weight Variation Test:

[0046] 20 capsules were Selected randomly. Weighed each intact capsule individually and recorded the total weight (W₁). the contents from each capsule were Carefully removed and the empty shell (W₂) were weighed. the net content weight was calculated:"Net content (mg)"=W_1-W_2

[0047] The average net weight of all capsules were calculated and % deviation for each capsule was determine using following formula :%"Deviation"=("Individual weight" -"Average weight" ) / "Average weight" x100Capsule No. Total Weight (mg) Empty Shell Weight (mg) Net Content (mg) % Deviation1 541 100 441 -1.78%2 542 100 442 -1.56%3 547 100 447 -0.45%4 551 100 451 +0.45%5 552 100 452 +0.67%6 550 100 450 +0.22%7 548 100 448 -0.22%8 551 100 451 +0.45%9 544 100 444 -1.11%10 552 100 452 +0.67%11 551 100 451 +0.45%12 543 100 443 -1.34%13 544 100 444 -1.11%14 540 100 440 -2.00%15 541 100 441 -1.78%16 545 100 445 -0.89%17 546 100 446 -0.67%18 537 100 437 -2.67%19 546 100 446 -0.67%20 551 100 451 +0.45%Average - - 449 mg -Table no. 01: Observation Table for weight variation:

[0048] All capsules were within ±7.5% weight variation, hence complied with USP / IP limits for weight uniformity.2. Disintegration Test:

[0049] 6 capsules were placeed in the tubes of the disintegration basket. Distilled water or 0.1N HCl (37 ± 2°C) was the medium. The apparatus was operated at 30 cycles per minute and observed until no residue remains on the mesh except insoluble fragments.Table no. 02: Observation Table for Disintegration Test:Capsule No. Disintegration Time (min) Medium Used Observation1 24 Water (37°C) Complete2 25 Water (37°C) Complete3 23 Water (37°C) Complete4 26 Water (37°C) Complete5 25 Water (37°C) Complete6 24 Water (37°C) CompleteAverage 24.5 min - All Disintegrated

[0050] All six capsules were disintegrated within 25 minutes, which is within USP / IP specified limit (≤30 min).Evaluation of Content Uniformity:

[0051] The content uniformity test of capsules containing three herbal extracts Swertia chirata extract, Fenugreek seed extract, and Bitter wood extract in the strength of 150 mg each was conducted.

[0052] Accordingly, a 100 ppm solution of each extract was prepared. This was used as the standard solution. Preparation of 100 ppm standard solutions:

[0053] 10 mg of each extract was weighed into separate 100 mL clean and dry volumetric flasks and then was dissolved in methanol and then made up with methanol and mixed well to prepare 100 ppm solution of each extract. Preparation of 100 ppm sample solutions for content uniformity test:

[0054] Take 10 capsules. Each capsule contains: 150 mg x 3 extracts = 450 mg total extract. Transfer contents of one capsule in to a 250 mL clean and dry volumetric flask. Add about 180 mL methanol. Sonicate for 30 minutes to ensure maximum extraction. Allow to cool to room temperature. Make up the volume to 250 mL with methanol. Mix well. Filter through Whatman No. 1 filter paper. Further transfer 8.4 mL of the filtrate to 50 mL clean and dry volumetric flask and make up the volume with methanol and mix well.Blank solution: Methanol was used as blank solution.Table no. 03: Results of content uniformity test: Extract Fenugreek seed extract Bitter wood extract Swertia chirata extractWavelength: 273 nm 340 nm 318 nmSolution name Reading % content Reading % content Reading % contentStandard solution 0.978 0.398 0.569 Sample solution-1 0.966 100.9 0.389 99.9 0.554 99.5Sample solution-2 0.953 99.6 0.388 99.6 0.548 98.4Sample solution-3 0.938 98.0 0.388 99.6 0.549 98.6Sample solution-4 0.933 97.5 0.389 99.9 0.559 100.4Sample solution-5 0.937 97.9 0.393 100.9 0.547 98.2Sample solution-6 0.959 100.2 0.390 100.1 0.557 100.0Sample solution-7 0.955 99.8 0.386 99.1 0.549 98.6Sample solution-8 0.934 97.6 0.387 99.4 0.551 99.0Sample solution-9 0.943 98.5 0.388 99.6 0.548 98.4Sample solution-10 0.955 99.8 0.386 99.1 0.552 99.1Average 99.0 99.7 99.0Standard deviation 1.2 0.5 0.7%RSD 1.2 0.5 0.7Acceptance value calculationAverage 99.0 99.7 99.0M 99.0 99.7 99.0k 2.4 2.4 2.4SD 1.2 0.5 0.7AV 2.9 1.3 1.8Conclusion: As per USP criteria, maximum allowed acceptance value L1 = 15.0 unless otherwise specified. Hence all results are within acceptance criteria.Evaluation of Dissolution

[0055] The dissolution test of capsules containing three herbal extracts Swertia chirata extract, Fenugreek seed extract, and Bitter wood extract in the strength of 150 mg each was performed. Accordingly, a 166 ppm solution of each extract was prepared. This was used as the standard solution. Preparation of 166 ppm standard solutions:

[0056] 16.6 mg of each extract was weighed into separate 100 mL clean and dry volumetric flasks and then was dissolved in 0.1 N HCl (pH -1.2) and then made up with 0.1 N HCl (pH -1.2) and mixed well to prepare 166 ppm solution of each extract. Preparation of 166 ppm sample solutions for dissolution test:

[0057] 6 capsules were taken, each capsule containing 150 mg x 3 extracts = 450 mg total extract. The capsule were transferred into different dissolution glass vessels containing 900 mL dissolution media maintained at 37ºC ± 0.5ºC. After the appropriate time interval withdraw 10 mL of aliquot from each vessel and filter through 0.45μm membrane filter. Reading were taken on UV spectrophotometer and calculated against respective standard solutions. Dissolution media was used as blank solution.Table no. 4: Dissolution conditions:Parameter ConditionDissolution media 0.1 N HCl (pH -1.2)Apparatus USP I - BasketVolume 900 mLTemperature 37 ± 0.5 °CSpeed 50 rpmTime interval 60 minutesTable no. 5: Dissolution Studies Percent drug release of each extractExtract Fenugreek seed extract Bitter wood extract Swertia chirata extractWavelength: 273 nm 340 nm 318 nmSolution name Reading % release Reading % release Reading % releaseStandard solution 0.955 0.412 0.607 Sample solution-1 0.944 98.5 0.407 98.4 0.601 98.6Sample solution-2 0.932 97.2 0.409 98.9 0.607 99.6Sample solution-3 0.951 99.2 0.410 99.1 0.606 99.4Sample solution-4 0.930 97.0 0.407 98.4 0.604 99.1Sample solution-5 0.948 98.9 0.407 98.4 0.605 99.3Sample solution-6 0.949 99.0 0.408 98.6 0.604 99.1Average 98.3 98.6 99.2Standard deviation 0.9 0.3 0.3%RSD 1.0 0.3 0.3Conclusion:

[0058] The acceptance criteria is ≥ 80% release in 60 min. Hence all results are within acceptance criteria.EVALUATION OF ANTIDIABETIC ACTIVITY OF HERBAL EXTRACTS:Table no. 6: Details of test conditions of study protocol Test substances Quassia amara, Swertia Chirata and Trigonella foenum-graecumDose • Quassia amara and Swertia Chirata 100mg / kg, 200mg / kg, 400 mg• Trigonella foenum-graecum 200 mg• Polyherbal formulation- Quassia amara and Swertia Chirata andTrigonella foenum-graecum 50 mgRoute ofadministration OralFood Standard Laboratory DietWater Aqua Guard Pure Water in polycarbonate bottles ad libitumRandomization, Grouping and numbering of animals:

[0059] Healthy wistar rats were divided in to 11 groups each (n=6) for oral administration. Acclimatized animals were weighed prior to test compound administration.Table no. 7: STZ induced diabetes in wistar ratsSr no Groups Treatment & dose-Route No. of animals1 Normal group Vehicle (10 ml / kg) 62 Diabetic control STZ 50 mg / kg, ip 63 Standard control Metformin 500 mg / kg 64 Test compound Quassia amara 100 mg / kg, oral 65 Test compound Quassia amara 200 mg / kg, oral 66 Test compound Quassia amara 400 mg / kg, oral 67 Test compound Swertia Chirata 100 mg / kg, oral 68 Test compound Swertia Chirata 200 mg / kg, oral 69 Test compound Swertia Chirata 400 mg / kg, oral 610 Test compound Trigonella foenum- graecum 200 mg / kg, oral 611 Polyherbal formulation (Quassia amara+ Swertia Chirata and Trigonella foenum-graecum 50 mg / kg, oral 6Total animal 66Preparation of Streptozotocin:Requirements: • Streptozotocin• 0.1M sodium citrate buffer solution• Streptozotocin was be dissolved in 0.1 M sodium citrate buffer solution (pH 4.5) to form a test solution.

[0060] Half Life of Streptozotocin preparation is known to be 10 mins ± 5 mins. Therefore, freshly prepared Streptozotocin solution was is injected immediately within 10-15 minutes of preparation with the dose of 50mg / kg. Streptozotocin causes selective destruction of cells of islets of pancreas and brings an increase in blood glucose levels.

[0061] Therefore, blood sugar level was be analyzed at various intervals of time after the administration of Streptozotocin solution.Preparation of sodium citrate buffer (0.1 m)

[0062] For the preparation of 0.1M Sodium citrate Buffer initially Citric acid solution was be formulated by dissolving 1.05gm of Citric acid monohydrate in 100 ml of deionized water.Tri Sodium citrate solution was be developed by adding 1.47gm Tri Sodium Citrate in 100 ml of deionized water.

[0063] Further 49.5 ml Citric acid solution was be amalgamated with 50.5 ml of Tri Sodium citrate solution to form 0.1M Sodium citrate Buffer.Preparation of test compound

[0064] Daily test Quassia amara, Swertia Chirata Trigonella foenum-graecum extracts were prepared freshly as stock solution of 100 mg / mL concentration of each test compound.

[0065] The prepared extracts were administered as 1 mL for 400 mg / kg dose, 0.5 mL for 200 mg / kg and 0.25 mL for 100 mg / kg doses for rat weighing 250 grams and other animals were received as per their respective volume as per their body weights.Experimental ProcedureInvivo antidiabetic activity in Streptozotocin induced diabetes in rats.Injection of Streptozotocin.

[0066] After the fasting period of 12 hours, Animals divided into various groups was be injected with a single intraperitoneal injection of Streptozotocin with the dose of 50mg / kg body weight in 0.1 M Sodium citrate buffer solution. After injecting, animals were being observed for the period of 7 days; blood glucose was be measured from the tail vein for a week for assessment of the diabetic state of the animals.Induction of diabetes in rats

[0067] Wister rats (8-12 weeks old, either sex), weighing 180-250 grams, was be acclimated to the laboratory environment. On the day of the Streptozotocin injection, each rat was being under glucose assessment.

[0068] For the investigation, animals with blood glucose levels between 80 and 110 mg / dl were are chosen.

[0069] All of the chosen animals were being intraperitoneal injected with freshly produced 50 mg / kg Streptozotocin in citrate buffer (pH 4.5).

[0070] The preparation of the Streptozotocin injection has to be completed in 20 minutes.

[0071] The blood glucose levels were be measured on day 4 of Streptozotocin injection, animal showing blood glucose more than 170 mg / dl to up to 350 mg / dl was be selected for the further studies.Administration of test substance:

[0072] The test substance was be administered by gavage according to the dose requirements of the specific groups.

[0073] The rats were being divided into 11 groups with six rats in each group.

[0074] All the animals were administered with their test extracts as per their body weight once a daily for 30 days to diabetic animals. Control group received only vehicle similar to diabetic control group.Blood withdrawal:

[0075] From the disease control group, all the rats should be subjected for blood withdrawal after 4 days post injection of Streptozotocin.

[0076] Under slight isoflurane anaesthesia, 0.1-0.2 mL blood should be withdrawn in 1.5 ml Eppendorf tubes containing EDTA or heparin from each rat.

[0077] To all the groups of animals, for blood withdrawal, similar procedure was is followed on the day of test drug administration.

[0078] On the day of test drug administration, the blood samples were is withdrawn weekly basis and glucose levels were is measured using ACU-CHECK glucometer INSTANT strip.

[0079] The plasma was separated and used for the estimation of insulin, TNF-alpha and Il-6.Plasma insulin; TNF alpha and IL-6 levels were checked.

[0080] After blood withdrawal, animals were sacrificed, liver and pancreas were isolated. Half portion of liver were subjected for hominization and used for estimation of lipid profile and antioxidant enzymes.

[0081] Remaing half portion of liver and pancreas were subjected for histopathological studies.Table no. 8: Effects of Quassia amara, Swertia Chirata and Trigonella foenum-graecum on body weight in streptozotocin induced diabetes in wistar rats.Treatment and Groups Body weight on various days (Grams; Mean±SD) Day 0 Week I Week II Week III Week IVNormal Group 223.67±12.6 234.00±12 / 9 246.17±14.3 258.00±14.7 270.83±10.4Diabetic Control(STZ 50 mg / kg) 211.67±11.3 204.00±8.7a 194.83±8.0a 186.50±7.1a 176.33±5.8aStandard Metformin 500 216.67±8.2 224.50±9.9 233.33±10.2 244.83±9.7b 257.50±9.0bQuassia amara100mg / kg 214.17±16.5 230.67±5.3 240.17±6.4 247.67±5.6 b 257.67±6.4 bQuassia amara 200mg / kg 229.33±15.9 224.00±16.0 235.62±14.9 246.50±13.2b 254.33±12.4bQuassia amara 400mg / kg 206.40±20.9 236.67±12.4 245.67±20.3 254.33±15.2b 262.17±16.3bSwertia Chirata100mg / kg 219.00±12.5 216.20±13.6 226.40±12.6 236.80±12.1b 245.00±11.7bSwertia Chirata200mg / kg 216.33±12.4 229.17±10.5 236.50±11.0 244.50±11.2b 253.00±9.9 bSwertia Chirata400mg / kg 227.73±19.3 225.50±13.4 232.00±13.0 240.33±12.1b 249.17±13.0bTrigonella foenum-graecum 200mg / kg, 213.17±18.2 233.50±17.5 241.00±18.1 250.17±'17 b 258.33±16.0bPolyherbal formulation (Quassia amara (50 mg / kg )+Swertia Chirata (50 mg / kg) and Trigonella foenum-graecum 50mg / kg) 216.12±9.5 225.00±9.4 235.00±7.9 245.00±10.0b 255.17±7.3bData was analyzed by Two Way ANOVA followed by Bonferroni post hoc. ap<0.001compared to normalcontrol of the respective week, bp<0.001 compared to diabetic control of the respective group.Table no. 9: Effects of Quassia amara, Swertia Chirata and Trigonella foenum-graecum on glucose levels in streptozotocin induced diabetes in wistar rats:Treatment and Groups Blood Glucose Level(mg / dl) on various days(weekly), Mean±SD Day 1 Week I Week II Week III Week IV Week VNormal Group 92.7±2.1 98.2±2.6 94.2±3.8 94.7±4.7 95.2±4.3 96.3±4.0Diabetic Control (STZ 50 mg / kg) 99.5±4.7 319.8± 143.4 a 307.5±114.4 a 319.2±95.5 a 313.2±71.0 a 295.7±51.9 aStandard Control Metformin 500 mg / kg 101.0±4.5 208.0±34.3 b 204.5±33.7 b 192.2±28.3 b 175.7±44.3 b 154.5±28.6 bQuassia amara 100mg / kg 95.3±5.3 251.0±36.2 b 192.0±23.6 b 191.0±23.9 b 259.3±38.3 b 258.2±30.0 bQuassia amara 200mg / kg 96.0±3.9 254.2±33.6 b 225.5±39.9 b 193.8±41.3 b 190.8±39.7 b 146.2±20.4 bQuassia amara 400mg / kg 95.0±4.6 251.0±37.5 b 217.7±23.1 b 186.7±13.8 b 174.7±10.3 b 154.2±10.5 bSwertia Chirata 100mg / kg 92.3±1.4 247.2±63.2 b 209.0±24.4 b 190.3±17.9 b 182.0±10.9 b 161.8±9.2 bSwertia Chirata200 mg / kg 179.3±3.4 179.2±12.4 b 172.5±11.4 b 159.5±14.4 b 140.3±12.3 b 179.3±12.4 bSwertia Chirata 400mg / kg 93.7±9.5 175.3±33.3 b 189.5±29.3 b 180.2±11.4 b 166.5±11.6 b 145.2±20.4 bTrigonella foenum-graecum 200mg / kg, 100.8±9.1 181.3±15.3 b 156.8±19.5 b 180.5±16.3 b 168.8±18 / 9 b 156.0±14.7 bPolyherbal formulation (Quassia amara (50 mg / kg )+Swertia Chirata (50 mg / kg) and Trigonella foenum-graecum (50mg / kg) 96.5±10.2 198.8±19.4 b 193.8±13.3 b 192.2±14.9 b 175.2±10.2 b 159.3±22.2 bData was analyzed by Two Way ANOVA followed by Bonferroni post hoc. ap<0.001compared to normal control of the respective week, bp<0.001 compared to diabetic control of the respective group.Table no. 10: Effects of Quassia amara, Swertia Chirata and Trigonella foenum- graecum on plasma insulin in streptozotocin induced diabetes in wistar rats Treatment and Groups Plasma insulin (ulU / ml, Mean±SEM)Normal Group 1018.60±266.83Diabetic Control (STZ 50 mg / kg) 45.36±12.32aStandard -Metformin 500 mg / kg 596.32±127.6 bQuassia amara 100mg / kg 212.10±33.8Quassia amara 200mg / kg 601.76±149.4 bQuassia amara 400mg / kg 764.87±41.34 bSwertia Chirata 100mg / kg 79.80±23.22Swertia Chirata 200 mg / kg 556.45±122.17 bSwertia Chirata 400mg / kg 935.23±167.9 bTrigonella foenum-graecum 200mg / kg, 1825.10±366.0 bPolyherbal formulation (Quassia amara (50 mg / kg)+Swertia Chirata (50 mg / kg) and Trigonella foenum-graecum (50mg / kg) 781.18±48.45 bData was analyzed by One Way ANOVA followed by Bonferroni post hoc. ap<0.001compared to normal control of the respective week, bp<0.001 compared to diabetic control of the respective group.Table no. 11: Effects of Quassia amara, Swertia Chirata and Trigonella foenum-graecum on TNF-α and IL-6 in streptozotocin induced diabetes in wistar rats: Treatment and dose Plasma TNF-α (pg / ml; Mean±SEM) Plasma IL-6 (ng / L; Mean±SEM)Normal Group 3.90±1.22 3.27±1.12Diabetic Control (STZ 50 mg / kg) 5.55±1.93 11.45±1.23###Standard Metformin 500 mg / kg 8.13±1.34 9.02±0.23Quassia amara 100mg / kg 7.57±0.93 5.00±0.92***Quassia amara 200mg / kg 15.11±2.43 5.25±0.86***Quassia amara 400mg / kg 10.70±1.09 3.87±0.56***Swertia Chirata 100mg / kg 2.43±0.73 4.64±0.69***Swertia Chirata200 mg / kg 3.17±0.44 3.99±0.82***Swertia Chirata 400mg / kg 9.04±1.33 11.53±2.42Trigonella foenum-graecum200mg / kg, 10.88±2.33 3.10±0.92***Polyherbal formulation (Quassia amara (50 mg / kg) +Swertia Chirata (50 mg / kg) and Trigonellafoenum-graecum (50mg / kg) 5.19±0.82 4.43±1.02Data was analyzed by One Way ANOVA followed by Bonferroni Post hoc test. ###p<0.001 compared tonormal control group, ** p<0.01, ***p<0.001 when compared to STZ control group. Table no. 12: Effect of QA or SC or Polyherbal formulation containing QA or SC with Trigonella foenum-graecum on antioxidant paradigm against STZ induced diabetic rats Treatment and dose Antioxidant parameters (μM / gm of proteins; Mean±SEM) SOD CAT GSHNormal Group 25.5±2.4 5.75±1.2 9.15±2.4Diabetic Control (STZ 50 mg / kg) 14.4±3.2 a 3.53±0.4a 5.58±0.5 aStandard Metformin 500 mg / kg 23.4±1.4 b 6.37±0.6 8.92±1.3 bQuassia amara 100mg / kg 28.09±4.7 b 7.57±0.1 b 7.5±0.8 bQuassia amara 200mg / kg 27.5±3.6 b 5.0±0.6 8.03±1.2 bQuassia amara 400mg / kg 19.9±3.3 b 5.1±0.9 6.5±1.5Swertia Chirata 100mg / kg 26.5±3.8 b 6.2±0.7 6.5±0.2Swertia Chirata200 mg / kg 26.2±2.4 b 5.5±0.9 b 4.5±0.3Swertia Chirata 400mg / kg 18.5±4.7 4.5±1.6 4.5±0.8Trigonella foenum-graecum 200mg / kg, 13.5±1.3 5.5±0.9 5.5±1.2Polyherbal formulation (Quassia amara (50 mg / kg) +Swertia Chirata (50 mg / kg) and Trigonella foenum-graecum (50mg / kg) 14.5±3.2 2.5±0.4 4.0±0.9Data was analyzed by One Way ANOVA followed by Bonferroni Post hoc test.ap<0.001compared to normal control of the respective week, bp<0.001 compared to diabetic control of the respective group.Table no. 13: Effect of QA or SC or Trigonella foenum-graecum and polyherbal formulation on plasma lipid profile in STZ induced diabetic ratsTreatment and dose Total cholesterol(mg / kg) Triglycerides(mg / kg) LDL(mg / kg) HDL(mg / kg)Normal Group 131.00±24.3 80.50±16.3 96.33±19.3 101.67±19.5Diabetic Control (STZ 50 mg / kg) 172.00±37.4a 137.50±32.5b 217.67±30.0b 55.00±7.1bStandard Metformin 500 mg / kg 150.67±30.3 91.67±12.2cc 150.17±22.2c 103.00±11.8cQuassia amara 100mg / kg 197.17±20.1 187.83±18.7 167.50±20.9c 171.00±11.4cQuassia amara 200mg / kg 203.33±25.3 167.67±14.2 165.17±20.4c 98.67±12.7cQuassia amara 400mg / kg 112.00±28.3 125.00±29.4 134.33±30.1cc 103.83±23.6ccSwertia Chirata 100mg / kg 210.17±29.6 189.00±53.9 183.50±40.5 104.00±16.0Swertia Chirata200 mg / kg 197.67±31.6 108.50±8.8c 134.83±9.0cc 143.83±16.7cSwertia Chirata 400mg / kg 188.00±18.5 139.50±15.5 134.33±30.7cc 126.00±27.6cTrigonella foenum-graecum200mg / kg, 159.17±42.4 109.17±37.1c 148.00±43.8 c 103.67±12.1 ccPolyherbal formulation (Quassia amara (50 mg / kg) +Swertia Chirata (50 mg / kg) andTrigonella foenum-graecum (50mg / kg) 140.83±16.3 124.00±19.5 106.33±21.5 114.17±12.7 ccData was analyzed by Two Way ANOVA followed by Bonferroni Post hoc test. ap<0.01, bp<0.001 compared to normal control group; cp<0.01, ccp<0.001, compared to STZ diabetic group.

[0082] In the present study, the antidiabetic activity was determined by invitro and in vivo studies. For In vivo study, diabetes was induced in wistar rats by injection of streptozotocin at 50 mg / kg by intraperitoneal injection. The diabetes was confirmed after 5 to 6 days in the wistar rats showing the blood glucose levels more than 170 mg / dl. The diabetic rats were divided into various groups and administered test compound Quassia amara, Sweritia Chirata at 100, 200 and 400 mg / kg and Trigonella foenu-graecum 200 mg / kg doses respectively daily for 30 days. The body weights and blood glucose levels were measured on weekly basis. In addition, plasma insulin, TNF-alpha and IL-6 levels and LDL, HDL, triglycerides and Cholesterol at the end of experiments were estimated in all the groups.

[0083] Further, antioxidants viz SOD, CAT, and GSH were estimated in liver homogenates. Test compounds also attenuated glucose levels in dose dependent manner. The standard metformin also exhibited reduction in glucose levels significantly. In addition, the TNF-alpha and IL-6 levels were found to significantly attenuated in dose dependent manner. Moreover, Quassia amara, Sweritia Chirata at 400 mg dose levels exhibited significant decrement in cytokines compared to diabetic control group. Trigonella foenum-graecum at 200 mg / kg improved the insulin levels post 15 days treatment in diabetic group which is corroborated with significant reduction in blood glucose levels post 15 days administration. moderate to severe hemorrhagic alterations in diabetic control. After treatment with test compound, Quassia amara, Sweritia Chirata Trigonella foenum-graecum and their formulation at 50 mg / kg mild degree of such changes. Further, metformin also ameliorated the histopathological alterations comparted to diabetic groups.

[0084] In conclusion, the Quassia amara, Sweritia Chirata Trigonella foenum-graecum at 200 and 400 mg / kg, polyherbal formulation exhibited significant antidiabetic activity mainly attenuation of cytokines TNF-alpha and IL-6, improves insulin released from pancreas and thus reduced the glucose levels, improved histopathological change.

[0085] The embodiments of the invention shown and discussed herein are merely illustrative of modes of application of the present invention. Reference to details in this discussion is not intended to limit the scope of the claims to these details, or to the figures used to illustrate the invention.

Claims

1. A polyherbal capsule formulation for diabetes mellitus management, comprising: (a) a standardized herbal extract blend prepared from an extract of Quassia amara, an extract of Swertia chirata and an extract of Trigonella foenum-graecum, wherein each extract is produced using a standardized extraction process that preserves bioactive phytochemical constituents, dried to yield a moisture content below 5% and subsequently milled and passed through a 60‐mesh sieve to produce a powder of uniform particle size; (b) a hard gelatin capsule encapsulating a predetermined dose of the powder blend, wherein the formulation is subjected to pre-formulation quality control tests including moisture content determination, particle size analysis and density measurements, and to post-formulation quality control tests including weight variation, disintegration and dissolution testing under pharmacopeial conditions.

2. The polyherbal capsule formulation of claim 1, wherein the standardized extraction process comprises ethanol extraction followed by drying to achieve a moisture content below 5%.

3. The polyherbal capsule formulation of claim 1, wherein the pharmaceutically acceptable excipients include at least one flow-enhancing agent selected from the group consisting of microcrystalline cellulose, starch and lactose.

4. The polyherbal capsule formulation of claim 1, wherein the powder blend is further adjusted by the addition of an extra 2-5% by weight of the total powder to compensate for process losses during encapsulation.

5. A method for preparing a polyherbal capsule formulation for diabetes mellitus management, the method comprising: (a) preparing standardized extracts of Quassia amara, Swertia chirata and Trigonella foenum-graecum by subjecting raw plant materials to an extraction process using ethanol, followed by drying to yield a moisture content below 5%; (b) milling the dried extracts and passing the resulting powders through a 60mesh sieve to obtain a uniform particle size, thereby forming individual extracts; (c) blending the extracts by geometric dilution with one or more pharmaceutically acceptable excipients to form a homogenous herbal extract blend; (d) encapsulating the powder blend into hard gelatin capsules to provide a predetermined dose per capsule; and (e) subjecting the encapsulated formulation to pre-formulation and post-formulation quality control tests including moisture content determination, particle size analysis, weight variation, disintegration and dissolution tests.